In this Article, we take a close look at two upcoming Biotech stocks in Gilead & Anika. Biotechs Gilead Sciences (NASDAQ GILD) and Anika Therapeutics (NASDAQ ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy point of a cup-with-handle base on June … Continue reading Active Biotech Stocks Gilead & Anika
Beats Electronics, which struck a deal to be acquired by Apple Inc. (NASDAQ AAPL) not too long ago, now faces a lawsuit filed by Bose Corporation. According to court documents, Bose has sued Beats in the U.S. District Court for the District of Delaware and filed a second complaint with the U.S. International Trade Commission. CNBC was the first to report the lawsuit. Bose Corporation … Continue reading Stock News: Bose Sues Apple Inc (NASDAQ AAPL) Owned Beats Over Patents
Google Inc (NASDAQ GOOG) released its second quarter results this week, and analysts from multiple firms are weighing in, as usual. JPMorgan analysts increased their price target for the search giant, while the Nomura team granted Google a “clean bill of health.” Shares of Google Inc (NASDAQ GOOG) rose more than 3% today after the company’s second quarter results. In a report dated July 18, … Continue reading Stock News: Google Inc (NASDAQ GOOG) Price Target Raised Due to Q2 Results
In the wake of Facebook Inc (NASDAQ FB)’s earnings report this week, analysts from multiple firms have increased their price targets and estimates. Two of the firms that raised their numbers are FBN and Baird. As always, mobile advertising and engagement rates are hot topics of conversation around the second quarter earnings results. Shares of Facebook Inc (NASDAQ FB) are holding their own after they … Continue reading Stocks Performing: Facebook (NASDAQ FB) Stock Price Targets Increased
The price of bitcoin on the CoinDesk USD Bitcoin Price Index has lost its long-time stability, dropping roughly 4% since the day’s open to sit at $595.73. This figure was up from the day’s low of $591.46, but down measurably from its high of $618.42, figures that baffled traders and reddit readers alike.
The day’s low was observed at 13:35 UTC and was followed by a sharp recovery, but it wasn’t enough to undo the mysterious and sudden decline. Prices on the CoinDesk CNY Bitcoin Price Index followed a similar trajectory, falling from an open of ¥3,832.17 to ¥3,692.45 at press time, but for once, even China wasn’t to blame for falling bitcoin prices.
With no clear news to blame for either the stability or the decline, many are wondering where to turn for answers.
Maybe bitcoin’s price needs more than good news. After all, people need time to figure out world-changing, disruptive technologies like bitcoin. Positive newsflow in the interim isn’t going to help the world adapt to our bitcoin future, no matter how many computers Dell sells.
Still, the drop on the CoinDesk Bitcoin Price Index from about $618 to $595 is nothing like the dramatic swings of late last year, when the digital currency first came under attack from the Chinese government, or earlier this year when the Mt. Gox bankruptcy news sent many Bitcoin investors rushing to the exits. But the decreasing volatility is just about what one would expect at this point in Bitcoin’s history.
Watch this video for more “News on Bitcoin”.
In the news on the Biotech Segment, we take a close look at three upcoming Biotech stocks in AbbVie, Bind Therapeutics & MannKind. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest. Per sources familiar with the dealings, AbbVie’s CEO Richard Gonzalez traveled to London recently to hold discreet … Continue reading Biotech Stocks to Watch: AbbVie, Bind Therapeutics & MannKind
